Moxifloxacin HCl

Catalog No.S1465 1 Product Citations

Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.

Price Stock Quantity  
In DMSO USD 160 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Moxifloxacin HCl Chemical Structure

Moxifloxacin HCl Chemical Structure
Molecular Weight: 437.89

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Moxifloxacin HCl is available in the following compound libraries:

Product Information

  • Compare Topoisomerase Inhibitors
    Compare Topoisomerase Products
  • Research Area

Product Description

Biological Activity

Description Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.
Targets Topoisomerase II [1] Topoisomerase IV [1]
In vitro Moxifloxacin exerts its effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. Moxifloxacin shows in-vitro potency against M. tuberculosis H37Rv with MIC of 0.177 μg/mL. Moxifloxacin has broad Grampositive and Gram-negative activity. Moxifloxacin shows in vitro and clinical efficacy against Staphylococcus aureus, Streptococcus pneumoniae, Str. pyogenes, Haemophilus influenzae, H. parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae and Mycoplasma pneumoniae. Moxifloxacin has activity against mycobacteria in addition to M. tuberculosis; Moxifloxacin is more active against M. kansasii than M. avium complex: specifically MIC90 for M. avium > M. intracellulare > M. kansasii at 4, 2 and 2 μg/mL, respectively. MIC90 for M. chelonae > M. fortuitum at 16 and 0.5 μg/mL, respectively. [1]
In vivo Moxifloxacin combined with RIF/pyrazinamide (PZA) reduces treatment time by up to 2 months compared to regimens with isoniazid (INH)/RIF/PZA in a mouse model designed to mimic human disease. Similar results with a stable cure are reached after 4 months in mice treated twice weekly with RIF/Moxifloxacin/PZA compared to cure in 6 months when daily treated with RIF/INH/PZA. 100 mg/kg Moxifloxacin in mice gives activity comparable to INH; increased dose in mice to 400 mg/kg Moxifloxacin daily results in spleen CFU counts lower than for INH 25 mg/kg although the differences are not statistically significant. AUC/MIC ratio correlates best with in-vivo efficacy for the fluoroquinolones in a mouse model of tuberculosis. [1]
Features

Protocol(Only for Reference)

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tuberculosis (Edinb), 2008, 88(2):127-131.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-09-20)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02236078 Not yet recruiting Tuberculosis|Drug-resistant Tuberculosis|Multidrug-resistant Tuberculosis Centers for Disease Control and Prevention|Kenya Medical  ...more Centers for Disease Control and Prevention|Kenya Medical Research Institute November 2014 --
NCT02236026 Not yet recruiting Healthy Population Council|Parexel September 2014 Phase 1
NCT02193776 Not yet recruiting Tuberculosis Global Alliance for TB Drug Development September 2014 Phase 2
NCT02217930 Not yet recruiting Qt Interval, Variation in Wockhardt August 2014 Phase 1
NCT02241759 Recruiting Dyslipidaemia Xention Ltd August 2014 Phase 1

view more

Chemical Information

Download Moxifloxacin HCl SDF
Molecular Weight (MW) 437.89
Formula

C21H24FN3O4.HCl

CAS No. 186826-86-8
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms BAY12-8039 HCl
Solubility (25°C) * In vitro DMSO 88 mg/mL (200 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Research Area

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Topoisomerase Products

Recently Viewed Items

Tags: buy Moxifloxacin HCl | Moxifloxacin HCl ic50 | Moxifloxacin HCl price | Moxifloxacin HCl cost | Moxifloxacin HCl solubility dmso | Moxifloxacin HCl purchase | Moxifloxacin HCl manufacturer | Moxifloxacin HCl research buy | Moxifloxacin HCl order | Moxifloxacin HCl mouse | Moxifloxacin HCl chemical structure | Moxifloxacin HCl mw | Moxifloxacin HCl molecular weight | Moxifloxacin HCl datasheet | Moxifloxacin HCl supplier | Moxifloxacin HCl in vitro | Moxifloxacin HCl cell line | Moxifloxacin HCl concentration | Moxifloxacin HCl nmr
Contact Us